Health Reversal Of Alzheimer's Symptoms Within Minutes In Human Study

[The Helper]

An extraordinary new scientific study, which for the first time documents marked improvement in Alzheimer’s disease within minutes of administration of a therapeutic molecule, has just been published in the Journal of Neuroinflammation.

This new study highlights the importance of certain soluble proteins, called cytokines, in Alzheimer’s disease. The study focuses on one of these cytokines, tumor necrosis factor-alpha(TNF), a critical component of the brain’s immune system. Normally, TNF finely regulates the transmission of neural impulses in the brain. The authors hypothesized that elevated levels of TNF in Alzheimer’s disease interfere with this regulation. To reduce elevated TNF, the authors gave patients an injection of an anti-TNF therapeutic called etanercept. Excess TNF-alpha has been documented in the cerebrospinal fluid of patients with Alzheimer’s.

Reversal Of Alzheimer's Symptoms Within Minutes In Human Study

An extraordinary new scientific study documents a dramatic and unprecedented therapeutic effect in an Alzheimer's patient: improvement within minutes following delivery of perispinal etanercept, which is etanercept given by injection in the spine.

www.sciencedaily.com

 

[The Helper]

If this was only true... sigh

 

[tom_mai78101]

Update to this news.



Pfizer Knew Its Drug Could Prevent Alzheimer’s. They Did Nothing About It, Says Post


In 2015, drug manufacturer Pfizer discovered that their drug Enbrel (etanercept), an anti-inflammatory used to treat rheumatoid arthritis, appeared to lower the risk of Alzheimer’s disease by a whopping 64 percent. No one ever learned about this discovery, however, because the company chose not to pursue any further investigation and decided not to release the findings. This comes from an investigative report released on Tuesday by The Washington Post.

Pfizer uncovered Enbrel’s potential for preventing Alzheimer’s during an analysis of hundreds of thousands insurance claims. Company documents obtained by The Washington Post state, “Enbrel could potentially safely prevent, treat and slow progression of Alzheimer’s disease.’’ However, figuring out if the drug would actually have that effect in people at risk of the disease would require an $80 million clinical trial.

After three years of internal debate, Pfizer decided against the trial, despite recommendations from researchers in the company’s division of inflammation and immunology. They also decided to keep their findings mum.

The company’s official stance today is that clinical trials weren’t likely to succeed because the molecules of the drug are too large to reach the brain. And the decision not to release their finding? Pfizer didn’t want to send outside researchers down a dead-end path.

This raises ethical questions about whether Pfizer had a responsibility to release this information to the scientific community. Alzheimer’s is, after all, a disease with at least 500,000 new diagnoses a year. While some experts say, yes, they absolutely should release those findings, others in the field of healthcare ethics claim that disclosures should be limited to information from clinical trials.

Pfizer Knew Its Drug Could Prevent Alzheimer’s. They Did Nothing About It, Says Post

Is Enbrel a viable treatment for Alzheimer's? Pfizer discovered that Enbrel (etanercept) could prevent the disease. But they hid the information.

www.beingpatient.com

The following article explains the design flaws of Dr. Edward Tobinick's study (mentioned in OP) in detail, and it is likely why Pfizer didn't pursue a clinical trial:

Enbrel for Stroke and Alzheimer’s

A recent article in the LA times tells of a husband’s quest to find a treatment for his wife’s Alzheimer’s disease. This is a narrative that journalists know and love—the brave patient or love

sciencebasedmedicine.org

 

[The Helper]

Oh that is just disturbing.